DNMT1 and neoplasm: Treatment with DNA methyltransferase (DNMT) inhibitors or EZH2 inhibitors has been shown to enhance responsiveness to immune checkpoint blockade and restore the production of Th1-type cytokines, thereby promoting a more effective anti-tumor immune response (94).